What are the efficacy and side effects of pemetinib/pemetinib?

Pemigatinib(Pemigatinib) is an oral small molecule targeted drug that has attracted great attention in the global oncology community in recent years. It belongs to the FGFR inhibitor class of drugs and mainly acts on the fibroblast growth factor receptor (FGFR) pathway. This pathway plays an important role in the occurrence and progression of various malignant tumors, especially in some patients with cholangiocarcinoma (CCA). FGFR2 gene fusion or rearrangement is considered to be an important factor driving tumors. Since traditional chemotherapy has limited efficacy in such patients, the development of drugs targeting FGFR has gradually become a breakthrough direction, and pemetinib is one of the representative results.

From the perspective of efficacy, the core value of pemetinib lies in precise treatment. It does not target all cancer patients, but uses genetic testing to screen out groups with FGFR2 abnormalities, thereby significantly improving the targeting and effectiveness of treatment. Multiple overseas clinical studies and real-world data show that patients using pemetinib show higher levels of disease control and remission rates, and some patients can even achieve long-term disease stability. Especially in advanced cholangiocarcinoma, the application of this oral targeted drug provides new hope for patients with limited previous treatment options. In addition to cholangiocarcinoma, pemetinib has also been explored in the field of myeloproliferative diseases and other solid tumors, showing certain potential, indicating that its efficacy is not limited to a single indication. It is worth noting that patients must undergo genetic testing before use, which is the key to ensuring efficacy.

However, like most targeted drugs, pemetinib may also cause a series of side effects while functioning, and its characteristics are closely related to its mechanism of action. Since drugs inhibit the FGFR pathway, one of the common side effects is an increase in blood phosphorus levels, which is related to the drug's effect on phosphorus metabolism. In order to control hyperphosphatemia, patients may need to adjust their dietary habits during treatment, such as reducing the intake of high-phosphate foods, or taking auxiliary drugs under the guidance of a doctor. In addition to metabolic effects, some patients may experience eye-related adverse reactions, such as dry eyes, blurred vision and even retinal abnormalities. Therefore, it is particularly important to conduct regular eye examinations during medication. In addition, mouth ulcers, fatigue, loss of appetite, rash, and nail changes are also common side effects. Although most are mild to moderate, they still require monitoring and intervention. For a small number of patients, if side effects are severe, doctors may adjust the dose or suspend treatment according to the situation to ensure the safety of the overall treatment.

It is worth emphasizing that the side effects of pemetinib are not uncontrollable, and its predictability and management methods are constantly improving. Doctors usually explain possible adverse reactions to patients before treatment and conduct close follow-up during the medication process. For example, regular testing of blood indicators, eye examinations, and guidance on dietary management and lifestyle adjustments can effectively reduce the incidence and severity of side effects. Compared with traditional chemotherapy, pemetinib is relatively well tolerated, and many patients can persist in taking it for a long time under standardized management, thereby achieving a more durable therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB15102